Minovia Therapeutics Overview
Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform. The companys initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments. The company developed a cell therapy approach to treat a broad range of indications generated by a mitochondrial dysfunction. Using its proprietary Mitochondrial Augmentation Technology (MAT), designed to be a robust therapeutic platform combining personalized mitochondrial cell therapy and scalable manufacturing processes, Minovia is advancing breakthrough therapies for patients with mitochondrial dysfunction, caused by disease as well as during aging. Minovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
Minovia Therapeutics Ltd., a clinical-stage biotechnology company, has entered into a definitive business combination agreement with Launch One Acquisition Corp., a special purpose acquisition company. This transaction will create a publicly traded entity focused on developing and commercializing Mitochondrial Augmentation Technology (MAT) to address diseases driven by mitochondrial dysfunction. The business combination is expected to close in the fourth quarter of 2025, providing Minovia with additional capital to accelerate its growth and development pipeline. The transaction assigns Minovia a pre-money equity valuation of $180 million, with additional PIPE investments anticipated. Minovias lead product, MNV-201, is in Phase 2 trials for Pearson Syndrome and has received FDA Fast Track Designation.
Public TradingPIPE/POInvestment
growth-positive
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
Minovia Therapeutics Ltd, a clinical-stage biopharmaceutical company, has announced that the FDA has cleared its second Investigational New Drug (IND) application for MNV-201, a mitochondrial cell therapy product. This clearance allows Minovia to initiate a Phase II clinical trial for pediatric patients with Pearson Syndrome, a severe mitochondrial disease. The trial aims to evaluate the safety and efficacy of MNV-201, focusing on improving growth and quality of life. The FDAs clearance marks a significant milestone for Minovia, enabling them to advance their allogeneic mitochondrial therapy approach. The study will enroll additional patients and is expected to provide insights into the potential benefits of MNV-201 for this patient population.
Product StageFDA approved/pending approval
growth-positive
New cell therapy may be key to curing disease - ISRAEL21c
Minovia Therapeutics, an Israeli company, is developing mitochondrial augmentation therapy (MAT) to treat rare mitochondrial diseases. The therapy involves enriching hematopoietic stem cells with healthy mitochondria and injecting them back into patients. The company has conducted successful trials on children with Pearson syndrome, a bone marrow disorder. The children showed improvement in aerobic function, weight gain, and strength. Minovia is now developing an off-the-shelf product using mitochondria from donated placentas. The first indication for the product is still Pearson syndrome, but the company plans to expand to other indications. Minovia intends to collaborate with big pharma companies and has already partnered with Astellas Pharma. The company has received investments totaling nearly $30 million and holds 70 patents. It has 46 employees, mostly female.
CustomersPartnersInvestmentManagement Changes
Minovia Therapeutics Announces Data from Preclinical Studies Demonstrating that Mitochondrial Augmentation of CD34+ cells Confers Functional Benefit and that Mitochondrial Transfer Occurs Between Hematopoietic Cells In Vivo
growth-positive
Astellas and Minovia Therapeutics Announce Strategic Collaboration for Novel Mitochondrial Cell Therapy Programs
Minovia Therapeutics and Astellas Pharma have announced a global strategic collaboration and license agreement for the research, development, and commercialization of novel cell therapy programs for diseases caused by mitochondrial dysfunction. The partnership aims to accelerate the creation of allogeneic mitochondrial cell therapy programs, with the two companies jointly researching cell therapy program candidates. Under the terms of the agreement, Minovia will receive an upfront cash payment of $20M USD from Astellas. If Astellas develops and commercializes product candidates for diseases caused by mitochondrial dysfunction, Minovia could receive up to $420M USD per product in future development, regulatory and commercial milestone payments from Astellas.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $28.35M |
| Last funding | $350K |
| Stage | Public |
| Rounds | 5 |
| Investors | 3 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | minoviatx.com |
| Careers | Careers page |
Locations
HaSadna 3, Tirat Carmel, Israel
Cambridge, Massachusetts, USA
Photos & Videos
1 item(s)
